25 related articles for article (PubMed ID: 1333369)
1. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II
Carvajal-Moreno J; Wang X; Hernandez VA; Mondal M; Zhao X; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2024 Apr; 389(2):186-196. PubMed ID: 38508753
[TBL] [Abstract][Full Text] [Related]
2.
Wang X; Carvajal-Moreno J; Zhao X; Li J; Hernandez VA; Yalowich JC; Elton TS
Mol Pharmacol; 2024 May; ():. PubMed ID: 38719474
[TBL] [Abstract][Full Text] [Related]
3. Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP2 poison anti-cancer drug etoposide.
Cowell IG; Austin CA
FEBS Open Bio; 2024 Mar; ():. PubMed ID: 38531625
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Cytotoxic Evaluation of Arimetamycin A and Its Daunorubicin and Doxorubicin Hybrids.
Huseman ED; Byl JAW; Chapp SM; Schley ND; Osheroff N; Townsend SD
ACS Cent Sci; 2021 Aug; 7(8):1327-1337. PubMed ID: 34471677
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Skladanowski A; Konopa J
Br J Cancer; 2000 Apr; 82(7):1300-4. PubMed ID: 10755405
[TBL] [Abstract][Full Text] [Related]
6. Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Hirohashi Y; Hidaka K; Sato S; Kuwano M; Kohno K; Hisatsugu T
Jpn J Cancer Res; 1995 Nov; 86(11):1097-105. PubMed ID: 8567402
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.
Souès S; Laval F; Charcosset JY
Br J Cancer; 1995 Mar; 71(3):489-97. PubMed ID: 7880729
[TBL] [Abstract][Full Text] [Related]
8. "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
Cimoli G; Valenti M; Noviello E; Parodi S; Mazzoni A; Rovini E; De Sessa F; Russo P
J Cancer Res Clin Oncol; 1995; 121(3):155-63. PubMed ID: 7713987
[TBL] [Abstract][Full Text] [Related]
9. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
10. The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance.
Lotz C; Lamour V
Cancer Drug Resist; 2020; 3(2):149-160. PubMed ID: 35582608
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.
Glisson BS; Killary AM; Merta P; Ross WE; Siciliano J; Siciliano MJ
Cancer Chemother Pharmacol; 1992; 31(2):131-8. PubMed ID: 1333369
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line.
Chan VT; Ng SW; Eder JP; Schnipper LE
J Biol Chem; 1993 Jan; 268(3):2160-5. PubMed ID: 8380592
[TBL] [Abstract][Full Text] [Related]
13. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Latham MD; Rowe TC; Ross WE
Biochemistry; 1989 Jun; 28(13):5680-7. PubMed ID: 2550059
[TBL] [Abstract][Full Text] [Related]
14. Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.
Glisson BS; Sullivan DM; Gupta R; Ross WE
NCI Monogr; 1987; (4):89-93. PubMed ID: 2819738
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
